LEXINGTON, Mass .– (COMMERCIAL THREAD) – Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company specializing in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced its public offering price initial 7,400,000 its common shares at an initial public offering price of $ 18.00 per share. All shares are offered by Cyteir. In addition, Cyteir has granted the Underwriters a 30-day option to purchase up to 1,110,000 additional Common Shares at the initial public offering price, less subscription rebates and commissions. The shares are expected to begin trading on the Nasdaq Global Select market on June 18, 2021 under the symbol “CYT”.
The gross proceeds of the Offer, before deducting any discounts and underwriting commissions and other estimated Offering fees payable by Cyteir, are expected to be approximately $ 133 million, excluding the exercise of the Underwriters’ option to purchase. additional actions. The closing of the offer is scheduled for June 22, 2021, subject to the satisfaction of the usual closing conditions.
JP Morgan, Morgan Stanley and BofA Securities act as co-book managers for the offering and Wedbush PacGrow acts as co-manager.
A registration statement relating to the shares sold under this offering was declared effective by the Securities and Exchange Commission on June 17, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, free of charge by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the final prospectus, when available, can be obtained from JP Morgan Securities LLC, c / o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803- 9204, or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by phone: 1-866-718-1649; or BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at: [email protected] com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy such securities, and there will be no sale of such securities in any State or other jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Cyteir Therapeutics, Inc.
Cyteir is a clinical-stage oncology company focused on the discovery and development of next-generation synthetic lethal therapies to treat cancer. The company is using its expertise in the biology of the DNA damage response to advance a pipeline of new drug candidates that selectively target key vulnerabilities to cancer. Cyteir’s flagship compound, CYT-0851, is a potent and selective oral investigational drug that has been designed to inhibit RAD51-mediated homologous recombination and repair of double-stranded DNA breaks.
This press release contains “forward-looking statements” regarding Cyteir’s plans for its proposed initial public offering. Forward-looking statements include statements regarding the proposed public offering and other statements identified by words such as “may”, “may”, “may”, “” seeks “,” believes “,” believes “,” s ‘expect to’, ‘continue’, ‘plans’ and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions about financial market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Therefore, actual results may differ materially from those contemplated by forward-looking statements. Important factors that could cause actual results to differ materially from those of forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including the risk regarding when Cyteir may complete. the offer and other factors under the heading âRisk Factorsâ in Cyteir’s registration statement on Form S-1. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The company does not undertake, and specifically disclaims, any obligation to update these statements or to publicly announce the results of any revision of these statements to reflect future events or developments, except as required by law.
For more information, please refer to the Company’s reports and documents filed with the United States Securities and Exchange Commission (SEC). You can obtain these documents by visiting EDGAR on the SEC’s website at www.sec.gov.